Seres Therapeutics, Inc.
MCRB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001609809
In the last 90 days, Seres Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 35 institutions reported holding it in 13F filings for Q2 2026, worth $17.9M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Seres Therapeutics, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Of which not filed for Q4 2021 | Q4 2021 | Change |
|---|---|---|---|---|
| Holders | 133 | 2 | 148 | +17 |
| Shares | 79.6M | 86.0K | 77.2M | −2.35M (−3.0%) |
| Value | $555.1M | $599.0K | $642.8M | +$88.3M (+15.9%) |
2 institutions that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (37)
Institutions that held Seres Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
Sold out (20)
Institutions that held Seres Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| AXA S.A. | 281,300 | $1.96M |
| Walleye Capital LLC | 217,662 | $1.51M |
| Gsa Capital Partners LLP | 200,028 | $1.39M |
| AlphaCentric Advisors LLC | 165,500 | $1.15M |
| LMR Partners LLP | 145,100 | $1.01M |
| First Trust Advisors LP | 68,940 | $480.0K |
| Occudo Quantitative Strategies LP | 63,919 | $445.0K |
| TD Asset Management Inc | 41,725 | $290.0K |
| HAP Trading, LLC | 40,044 | $279.0K |
| Handelsbanken Fonder AB | 36,500 | $254.0K |
| Bank Julius Baer & Co. Ltd, Zurich | 36,249 | $252.0K |
| Walleye Trading LLC | 35,591 | $248.0K |
| Cowen and Company, LLC | 12,490 | $87.0K |
| KBC Group NV | 5,240 | $36.0K |
| Gilder Gagnon Howe & Co LLC | 3,380 | $24.0K |
| Caption Management, LLC | 3,250 | $23.0K |
| Penserra Capital Management LLC | 2,100 | $14.0K |
| Meeder Asset Management Inc | 1,403 | $9.00K |
| Evolution Wealth Advisors, LLC | 748 | $5.00K |
| Concord Wealth Partners | 53 | $0 |
Not filed for Q4 2021 yet (2)
Institutions that held Seres Therapeutics, Inc. at the end of Q3 2021 and haven't filed a 13F for Q4 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Marshall Wace North America L.P. | 85,755 | $598.0K |
| Berman Capital Advisors, LLC | 244 | $1.00K |